España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Nektar Therapeutics
NKTR
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.8506
0.01
1.61%
At close: -
$0.8506
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Nektar Therapeutics (NKTR) Forecast
News
Earnings
Nektar Therapeutics (NKTR) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics Stock (NASDAQ: NKTR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 13, 2025
HC Wainwright & Co. Reiterates Buy on Nektar ...
Benzinga Newsdesk
Friday, January 10, 2025
Nektar Therapeutics Completes Target Enrollme...
Benzinga Newsdesk
Wednesday, January 08, 2025
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Avi Kapoor
B. Riley Securities Initiates Coverage On Nek...
Benzinga Newsdesk
Saturday, December 07, 2024
Nektar Therapeutics Announced NKTR-255 Follow...
Benzinga Newsdesk
Monday, November 18, 2024
Nektar Therapeutics Presents First Preclinica...
Benzinga Newsdesk
Thursday, November 07, 2024
Nektar Therapeutics Q3 2024 GAAP EPS $(0.18) ...
Benzinga Newsdesk
Nektar And Collaborators Present Late-Breakin...
Benzinga Newsdesk
Monday, November 04, 2024
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Vandana Singh
Nektar Therapeutics shares are trading higher...
Benzinga Newsdesk
Nektar Therapeutics To Sell Its Commercial PE...
Benzinga Newsdesk
10 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Piper Sandler Initiates Coverage On Nektar Th...
Benzinga Newsdesk
Tuesday, October 29, 2024
Data From Nektar's Multiple Phase 1b Studies ...
Benzinga Newsdesk
Nektar Publishes Results From Phase 1b Studie...
Benzinga Newsdesk
Thursday, October 17, 2024
Nektar Announces Publication In Blood Of Phas...
Benzinga Newsdesk
Monday, September 30, 2024
BTIG Assumes Nektar Therapeutics at Buy, Anno...
Benzinga Newsdesk
Wednesday, September 25, 2024
Nektar Therapeutics Announced Several Present...
Benzinga Newsdesk
Friday, August 09, 2024
Nektar's Q2 Earnings Lag Estimates, Revenues Top
Zacks
Thursday, August 08, 2024
Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) ...
Benzinga Newsdesk
Wednesday, June 12, 2024
Nektar Therapeutics Presents First Preclinica...
Benzinga Newsdesk
Friday, May 10, 2024
Nektar Therapeutics shares are trading higher...
Benzinga Newsdesk
Thursday, May 09, 2024
Nektar Therapeutics Q1 2024 GAAP EPS $(0.19) ...
Benzinga Newsdesk
Tuesday, May 07, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Tuesday, April 30, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Wednesday, April 17, 2024
Nektar Therapeutics Receives Letter That It H...
Benzinga Newsdesk
Thursday, April 11, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Wednesday, March 06, 2024
Jefferies Maintains Hold on Nektar Therapeuti...
Benzinga Newsdesk
Tuesday, March 05, 2024
Nektar Therapeutics Announces Initiation Of P...
Benzinga Newsdesk
Monday, March 04, 2024
Nektar Therapeutics Q4 2023 GAAP EPS $(0.22) ...
Benzinga Newsdesk
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
Nektar Therapeutics shares are trading higher...
Benzinga Newsdesk
Nektar Therapeutics Announces $30M Private Pl...
Benzinga Newsdesk
Earnings Scheduled For March 4, 2024
Benzinga Insights
Friday, March 01, 2024
Nektar Therapeutics Earnings Preview
Benzinga Insights
Friday, January 12, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
Monday, December 11, 2023
Nektar And Collaborators Present Preclinical ...
Benzinga Newsdesk
Monday, November 20, 2023
JP Morgan Reinstates Underweight on Nektar Th...
Benzinga Newsdesk
Thursday, November 09, 2023
TD Cowen Upgrades Nektar Therapeutics to Outp...
Benzinga Newsdesk
Tuesday, November 07, 2023
Recap: Nektar Therapeutics Q3 Earnings
Benzinga Insights
Earnings Scheduled For November 7, 2023
Benzinga Insights
Monday, November 06, 2023
A Preview Of Nektar Therapeutics's Earnings
Benzinga Insights
Friday, October 13, 2023
Nektar Presents New Responder Data For Rezpeg...
Benzinga Newsdesk
Monday, October 02, 2023
Nektar Therapeutics Announces Two Abstracts A...
Benzinga Newsdesk
Wednesday, September 27, 2023
Nektar Therapeutics Announces New Clinical St...
Benzinga Newsdesk
Friday, September 22, 2023
Director at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares
Benzinga Insights
Thursday, September 21, 2023
Director at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares
Benzinga Insights
Board Member at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares
Benzinga Insights
Nektar Therapeutics Board Member Awarded $59K Worth of Stock Options
Benzinga Insights
Wednesday, September 13, 2023
Nektar Therapeutics Announces Promising New D...
Benzinga Newsdesk
Show More
